Table of Content

1. Key Insights

2. Executive Summary of Complex Regional Pain Syndrome (CRPS)

3. SWOT Analysis

4. Epidemiology and Market Forecast Flow

5. Complex Regional Pain Syndrome (CRPS): Market Overview at a Glance
5.1. Total Market Share (%) Distribution of CRPS in 2017
5.2. Total Market Share (%) Distribution of CRPS in 2030

6. Complex Regional Pain Syndrome (CRPS): Disease Background and Overview
6.1. Introduction
6.2. Symptoms
6.3. Causes
6.4. Outcomes of CRPS
6.5. Clinical presentations
6.6. Natural course of CRPS
6.7. Classification
6.8. Pathophysiology
6.9. Diagnosis
6.9.1. Investigations
6.9.2. Imaging Techniques
6.9.3. Non-invasive imaging techniques
6.9.4. Thermography
6.9.5. Sudomotor Function Tests
6.9.6. Neurophysiological Tests
6.9.7. Examination
6.9.8. Differential diagnosis
6.10. Diagnostic Guidelines for CRPS
6.10.1. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 4th Edition - the USA
6.10.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults
6.10.3. Japanese CRPS diagnostic criteria

7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Prevalent Cases of CRPS in the 7MM
7.3.2. Total Diagnosed Prevalent cases of CRPS in the 7MM
7.3.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM
7.3.4. Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM
7.3.5. Type-specific Diagnosed Prevalent Cases of CRPS in 7MM
7.3.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in the 7MM
7.3.7. Treated cases of CRPS in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Prevalent Cases of CRPS in the United States
7.4.2. Total Diagnosed Prevalent cases of CRPS in the United States
7.4.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the United States
7.4.4. Age-specific Diagnosed Prevalent Cases of CRPS in the United States
7.4.5. Type-specific Diagnosed Prevalent Cases of CRPS in the United States
7.4.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in the United States
7.4.7. Treated cases of CRPS in the United States
7.5. EU-5 Epidemiology
7.6. Germany
7.6.1. Total Prevalent Cases of CRPS in Germany
7.6.2. Total Diagnosed Prevalent cases of CRPS in Germany
7.6.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Germany
7.6.4. Age-specific Diagnosed Prevalent Cases of CRPS in Germany
7.6.5. Type-specific Diagnosed Prevalent Cases of CRPS in Germany
7.6.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Germany
7.6.7. Treated cases of CRPS in Germany
7.7. France
7.7.1. Total Prevalent Cases of CRPS in France
7.7.2. Total Diagnosed Prevalent cases of CRPS in France
7.7.3. Gender-specific Diagnosed Prevalent Cases of CRPS in France
7.7.4. Age-specific Diagnosed Prevalent Cases of CRPS in France
7.7.5. Type-specific Diagnosed Prevalent Cases of CRPS in France
7.7.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in France
7.7.7. Treated cases of CRPS in France
7.8. Italy
7.8.1. Total Prevalent Cases of CRPS in Italy
7.8.2. Total Diagnosed Prevalent cases of CRPS in Italy
7.8.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Italy
7.8.4. Age-specific Diagnosed Prevalent Cases of CRPS in Italy
7.8.5. Type-specific Diagnosed Prevalent Cases of CRPS in Italy
7.8.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Italy
7.8.7. Treated cases of CRPS in Italy
7.9. Spain
7.9.1. Total Prevalent Cases of CRPS in Spain
7.9.2. Total Diagnosed Prevalent cases of CRPS in Spain
7.9.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Spain
7.9.4. Age-specific Diagnosed Prevalent Cases of CRPS in Spain
7.9.5. Type-specific Diagnosed Prevalent Cases of CRPS in Spain
7.9.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Spain
7.9.7. Treated cases of CRPS in Spain
7.10. The United Kingdom
7.10.1. Total Prevalent Cases of CRPS in the United Kingdom
7.10.2. Total Diagnosed Prevalent cases of CRPS in the United Kingdom
7.10.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
7.10.4. Age-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
7.10.5. Type-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
7.10.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
7.10.7. Treated cases of CRPS in the United Kingdom
7.11. Japan Epidemiology
7.11.1. Total Prevalent Cases of CRPS in Japan
7.11.2. Total Diagnosed Prevalent cases of CRPS in Japan
7.11.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Japan
7.11.4. Age-specific Diagnosed Prevalent Cases of CRPS in Japan
7.11.5. Type-specific Diagnosed Prevalent Cases of CRPS in Japan
7.11.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Japan
7.11.7. Treated cases of CRPS in Japan

8. Treatment and Management of CRPS
8.1. Treatment Guidelines
8.1.1. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 4th Edition - the USA
8.1.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults

9. Unmet Needs

10. Patient Journey

11. Key Endpoints in CRPS Clinical Trials

12. Emerging Therapies
12.1. Key Cross Competition
12.2. Soticlestat (TAK-935/OV935): Ovid Therapeutics/Takeda
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.3. BHV-5000: AstraZeneca/Biohaven Pharmaceutical
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development

13. CRPS: Seven Major Market Analysis
13.1. Key Findings
13.2. Market Outlook: 7MM
13.3. 7MM Market Size
13.3.1. Total Market Size of CRPS in the 7MM
13.3.2. Total Market size of CRPS by Therapies in the 7MM
13.4. United States Market Size
13.4.1. Total Market size of CRPS in the United States
13.5. EU-5 Market Size
13.6. Germany Market Size
13.6.1. Total Market size of CRPS in Germany
13.7. France Market Size
13.7.1. Total Market size of CRPS in France
13.8. Italy Market Size
13.8.1. Total Market size of CRPS in Italy
13.9. Spain Market Size
13.9.1. Total Market size of CRPS in Spain
13.10. United Kingdom Market Size
13.10.1. Total Market size of CRPS in the United Kingdom
13.11. Japan Market Size
13.11.1. Total Market size of CRPS in Japan

14. Market Access and Reimbursement

15. Market Drivers

16. Market Barriers

17. Appendix
17.1. Bibliography
17.2. Report Methodology

18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight



List of Figures


Figure 1 CRPS SWOT Analysis
Figure 2 Complex regional pain syndrome - CRPS
Figure 3 Typical features of a patient with CRPS
Figure 4 Causes of CRPS
Figure 5 Model for the development of complex regional pain syndrome (CRPS) from nerve injury
Figure 6 Speculative model of interacting mechanisms involved in the development of CRPS
Figure 7 Total Prevalent Cases of CRPS in the 7MM (2017–2030)
Figure 8 Total Diagnosed Prevalent cases of CRPS in the 7MM (2017–2030)
Figure 9 Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017–2030)
Figure 10 Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017–2030)
Figure 11 Type-specific Diagnosed Prevalent Cases of CRPS in 7MM (2017–2030)
Figure 12 Severity-Specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017–2030)
Figure 13 Treated cases of CRPS in the 7MM (2017–2030)
Figure 14 Total Prevalent Cases of CRPS in the United States (2017–2030)
Figure 15 Total Diagnosed Prevalent cases of CRPS in the United States (2017–2030)
Figure 16 Gender-specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Figure 17 Age-specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Figure 18 Type-specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Figure 19 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Figure 20 Treated cases of CRPS in the United States (2017–2030)
Figure 21 Total Prevalent Cases of CRPS in Germany (2017–2030)
Figure 22 Total Diagnosed Prevalent cases of CRPS in Germany (2017–2030)
Figure 23 Gender-specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Figure 24 Age-specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Figure 25 Type-specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Figure 26 Severity-Specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Figure 27 Treated cases of CRPS in Germany (2017–2030)
Figure 28 Total Prevalent Cases of CRPS in France (2017–2030)
Figure 29 Total Diagnosed Prevalent cases of CRPS in France (2017–2030)
Figure 30 Gender-specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Figure 31 Age-specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Figure 32 Type-specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Figure 33 Severity-Specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Figure 34 Treated cases of CRPS in France (2017–2030)
Figure 35 Total Prevalent Cases of CRPS in Italy (2017–2030)
Figure 36 Total Diagnosed Prevalent cases of CRPS in Italy (2017–2030)
Figure 37 Gender-specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Figure 38 Age-specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Figure 39 Type-specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Figure 40 Severity-Specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Figure 41 Treated cases of CRPS in Italy (2017–2030)
Figure 42 Total Prevalent Cases of CRPS in Spain (2017–2030)
Figure 43 Total Diagnosed Prevalent cases of CRPS in Spain (2017–2030)
Figure 44 Gender-specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Figure 45 Age-specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Figure 46 Type-specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Figure 47 Severity-Specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Figure 48 Treated cases of CRPS in Spain (2017–2030)
Figure 49 Total Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Figure 50 Total Diagnosed Prevalent cases of CRPS in the United Kingdom (2017–2030)
Figure 51 Gender-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Figure 52 Age-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Figure 53 Type-specific Diagnosed Prevalent Cases of CRPS in the United kingdom (2017–2030)
Figure 54 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Figure 55 Treated cases of CRPS in the United Kingdom (2017–2030)
Figure 56 Total Prevalent Cases of CRPS in Japan (2017–2030)
Figure 57 Total Diagnosed Prevalent cases of CRPS in Japan (2017–2030)
Figure 58 Gender-specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Figure 59 Age-specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Figure 60 Type-specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Figure 61 Severity-Specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Figure 62 Treated cases of CRPS in Japan (2017–2030)
Figure 63 Treatment algorithm
Figure 64 Four pillars of treatment for CRPS – an integrated interdisciplinary approach
Figure 65 Pathophysiology and mechanism-based treatment options in CRPS
Figure 66 CRPS rehabilitation algorithm for occupational therapists and physiotherapists
Figure 67 Unmet Needs of CRPS
Figure 68 Market Size of CRPS in the 7MM, in USD Million (2017–2030)
Figure 69 Market Size of CRPS in the 7MM by Therapies, in USD Million (2017–2030)
Figure 70 Market Size of CRPS in the United States by Therapy, in USD Million (2017–2030)
Figure 71 Market Size of CRPS in Germany by Therapies, in USD Million (2017–2030)
Figure 72 Market Size of CRPS in France by therapies, in USD Million (2017–2030)
Figure 73 Market Size of CRPS in Italy by Therapies, in USD Million (2017–2030)
Figure 74 Market Size of CRPS in Spain by therapies, in USD Million (2017–2030)
Figure 75 Market Size of CRPS in the United Kingdom by Therapies, in USD Million (2017–2030)
Figure 76 Market Size of CRPS in Japan by Therapy, in USD Million (2017–2030)
Figure 77 Market Drivers
Figure 78 Market Barriers


List of Tables


Table 1 Summary of CRPS, Market, Epidemiology, and Key Events (2017–2030)
Table 2 Comparison of CRPS Types
Table 3 Common characteristics of CRPS
Table 4 Stages of CRPS
Table 5 IASP clinical diagnostic criteria for CRPS - Budapest Criteria (2012)
Table 6 Difference between CRPS Types
Table 7 Possible mechanisms involved in complex regional pain syndrome
Table 8 Summary of pathophysiologic mechanisms that may contribute to CRPS
Table 9 Differential Diagnosis
Table 10 Technical investigations helpful to exclude a differential diagnosis
Table 11 Differential Diagnosis
Table 12 Levels of evidence
Table 13 Original International Association for the Study of Pain (Orlando) diagnostic criteria for complex regional pain syndrome
Table 14 Factors (and factor loadings) resulting from principal components factor analysis of diagnostic and associated signs and symptoms of CRPS
Table 15 Clinical diagnostic criteria for CRPS
Table 16 Summary of sensitivity and specificity of the clinical and research criteria
Table 17 Diagnosis of CRPS – Recommendations
Table 18 Referral – Recommendations
Table 19 Surgical practice – Diagnostic Recommendations
Table 20 Diagnosis of CRPS in emergency medicine - Recommendations
Table 21 The Veldman criteria
Table 22 Factors (and factor loadings) resulting from factor analysis of CRPS-related signs/symptoms
Table 23 Japanese CRPS diagnostic criteria for clinical purposes
Table 24 Total Prevalent Cases of CRPS in the 7MM (2017–2030)
Table 25 Total Diagnosed Prevalent cases of CRPS in the 7MM (2017–2030)
Table 26 Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017–2030)
Table 27 Age-specific Prevalent Cases of CRPS in the 7MM (2017–2030)
Table 28 Type-specific Diagnosed Prevalent Cases of CRPS in 7MM (2017–2030)
Table 29 Severity-Specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017–2030)
Table 30 Total Treated cases of CRPS in the 7MM (2017–2030)
Table 31 Total Prevalent Cases of CRPS in the United States (2017–2030)
Table 32 Total Diagnosed Prevalent cases of CRPS in the United States (2017–2030)
Table 33 Gender-specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Table 34 Age-specific Prevalent Cases of CRPS in the United States (2017–2030)
Table 35 Type-specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Table 36 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Table 37 Total Treated cases of CRPS in the United States (2017–2030)
Table 38 Total Prevalent Cases of CRPS in Germany (2017–2030)
Table 39 Total Diagnosed Prevalent cases of CRPS in Germany (2017–2030)
Table 40 Gender-specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Table 41 Age-specific Prevalent Cases of CRPS in Germany (2017–2030)
Table 42 Type-specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Table 43 Severity-Specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Table 44 Total Treated cases of CRPS in Germany (2017–2030)
Table 45 Total Prevalent Cases of CRPS in France (2017–2030)
Table 46 Total Diagnosed Prevalent cases of CRPS in France (2017–2030)
Table 47 Gender-specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Table 48 Age-specific Prevalent Cases of CRPS in France (2017–2030)
Table 49 Type-specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Table 50 Severity-Specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Table 51 Total Treated cases of CRPS in France (2017–2030)
Table 52 Total Prevalent Cases of CRPS in Italy (2017–2030)
Table 53 Total Diagnosed Prevalent cases of CRPS in Italy (2017–2030)
Table 54 Gender-specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Table 55 Age-specific Prevalent Cases of CRPS in Italy (2017–2030)
Table 56 Type-specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Table 57 Severity-Specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Table 58 Total Treated cases of CRPS in Italy (2017–2030)
Table 59 Total Prevalent Cases of CRPS in Spain (2017–2030)
Table 60 Total Diagnosed Prevalent cases of CRPS in Spain (2017–2030)
Table 61 Gender-specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Table 62 Age-specific Prevalent Cases of CRPS in Spain (2017–2030)
Table 63 Type-specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Table 64 Severity-Specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Table 65 Total Treated cases of CRPS in Spain (2017–2030)
Table 66 Total Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Table 67 Total Diagnosed Prevalent cases of CRPS in the United Kingdom (2017–2030)
Table 68 Gender-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Table 69 Age-specific Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Table 70 Type-specific Diagnosed Prevalent Cases of CRPS in the United kingdom (2017–2030)
Table 71 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Table 72 Total Treated cases of CRPS in the United Kingdom (2017–2030)
Table 73 Total Prevalent Cases of CRPS in Japan (2017–2030)
Table 74 Total Diagnosed Prevalent cases of CRPS in Japan (2017–2030)
Table 75 Gender-specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Table 76 Age-specific Prevalent Cases of CRPS in Japan (2017–2030)
Table 77 Type-specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Table 78 Severity-Specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Table 79 Total Treated cases of CRPS in Japan (2017–2030)
Table 80 Pharmacotherapy guide
Table 81 Management of suspected or confirmed CRPS - Recommendations
Table 82 Therapeutic approaches
Table 83 Yellow Flags
Table 84 Examples of CRPS-specific rehabilitation techniques
Table 85 Occupational therapy and physiotherapy- Recommendations
Table 86 Surgical practice – Management Recommendations
Table 87 Surgery to amputate the CRPS-affected limb - Recommendations
Table 88 Management and referral of CRPS in emergency medicine - Recommendations
Table 89 Management of CRPS in pain clinics
Table 90 Management of CRPS in pain clinics-referral
Table 91 Management of patients with CRPS and complex needs
Table 92 Long-term support in CRPS
Table 93 Key Cross Competition of Emerging Drugs
Table 94 Soticlestat (TAK-935/OV935), Clinical Trial Description, 2020
Table 95 List of Few Discontinued Drugs for CRPS
Table 96 7MM Market Size of CRPS, in USD Million (2017–2030)
Table 97 7MM Market Size of CRPS by Therapies, in USD Million (2017–2030)
Table 98 United States Market Size of CRPS by Therapies, in USD Million (2017–2030)
Table 99 Germany Market Size of CRPS by Therapies, in USD Million (2017–2030)
Table 100 France Market Size of CRPS by Therapies, in USD Million (2017–2030)
Table 101 Italy Market Size of CRPS by Therapies, in USD Million (2017–2030)
Table 102 Spain Market Size of CRPS by Therapies, in USD Million (2017–2030)
Table 103 United Kingdom Market Size of CRPS by Therapies, in USD Million (2017–2030)
Table 104 Japan Market Size of CRPS by Therapies, in USD Million (2017–2030)